Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency

Rheumatology (United Kingdom)

Volumn 51, Issue 10, 2012, Pages 1855-1859

  Galeotti, Caroline ^a   Meinzer, Ulrich ^a   Quartier, Pierre ^b   Rossi Semerano, Linda ^a   Bader Meunier, Brigitte ^b   Pillet, Pascal ^c   Koné Paut, Isabelle ^a  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Anakinra; Auto inflammatory disease; Canakinumab; Hyper IgD syndrome; Interleukin 1; Mevalonate kinase deficiency

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; BETAMETHASONE; C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; CYCLOSPORIN; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INTERLEUKIN 1; PARACETAMOL; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERUM AMYLOID A;

ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; CYTOLYSIS; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; HEPATITIS; HUMAN; HYPOTHERMIA; INFECTION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; KIDNEY TRANSPLANTATION; MEVALONATE KINASE DEFICIENCY; PHARYNGITIS; PRIORITY JOURNAL; PROTEIN TARGETING; QUESTIONNAIRE; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; SHIVERING; SIDE EFFECT; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MEVALONATE KINASE DEFICIENCY; TREATMENT OUTCOME;

EID: 84867131436     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes097     Document Type: Article

References (16)

1. Tsimaratos M, Kone-Paut I, Divry P, Philip N, Chabrol B. Mevalonic aciduria and hyper-IgD syndrome: two sides of the same coin? J Inherit Metab Dis 2001;24:413-4.
2. Bader-Meunier B, Florkin B, Sibilia J et al. Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 2011; 128:e152-9.
3. van der Hilst JC, Bodar EJ, Barron KS et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine 2008;87:301-10.
4. Obici L, Manno C, Muda AO et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2004;50:2966-9.
5. Simon A, Drewe E, van der Meer JW et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004;75:476-83.
6. Takada K, Aksentijevich I, Mahadevan V et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51.
7. Topaloglu R, Ayaz NA, Waterham HR et al. Hyperimmunoglobulinemia D and periodic fever syndrome: treatment with etanercept and follow-up. Clin Rheumatol 2008;27:1317-20.
8. Frenkel J, Rijkers GT, Mandey SH et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2002;46: 2794-803.
9. Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 2005;63:260-4.
10. Cailliez M, Garaix F, Rousset-Rouviere C et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 2006;29:763.
11. Rigante D, Ansuini V, Bertoni B et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006;27:97-100.
12. Nevyjel M, Pontillo A, Calligaris L et al. Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency. Pediatrics 2007;119:e523-7.
13. Lequerre T, Vittecoq O, Pouplin S et al. Mevalonate kinase deficiency syndrome with structural damage responsive to anakinra. Rheumatology 2007;46:1860-2.
14. Bodar EJ, Kuijk LM, Drenth JP et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 2011;70:2155-8.
15. Neven B, Valayannopoulos V, Quartier P et al. Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med 2007;356:2700-3.
16. Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis 2006;1:13.